NCT01746147View on ClinicalTrials.gov

Assessment of Body, Liver and Labile Plasma Iron and Their Association With Outcome and Immunological Recovery in Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Stem Cell Transplantation - ALLIVE (ALLogeneic Iron inVEstigators) Observational Trial

CompletedOBSERVATIONAL
Enrollment

134

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2016

Conditions
MDS and AML Prior to Allogeneic SCT
Interventions
OTHER

No intervention and study treatment

Trial Locations (5)

53127

Medizinische Klinik und Poliklinik III Abteilung für Hämatologie und Onkologie Universitätsklinikum Bonn, Bonn

60590

Universitätsklinikum MKII, Hämatologie/Onkologie, Universitäres Zentrum für Tumorerkrankungen, Frankfurt am Main

68167

III. Medizinischen Klinik Hämatologie und Internistische Onkologie Universitätsmedizin Mannheim, Mannheim

81675

III. Medizinischen Klinik des Klinikums rechts der Isar, München

01307

Universitätsklinikum Carl Gustav Carus der TU Dresden Medizinische Klinik und Poliklinik I, Dresden

All Listed Sponsors
lead

GWT-TUD GmbH

OTHER

NCT01746147 - Assessment of Body, Liver and Labile Plasma Iron and Their Association With Outcome and Immunological Recovery in Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) Patients Undergoing Allogeneic Stem Cell Transplantation - ALLIVE (ALLogeneic Iron inVEstigators) Observational Trial | Biotech Hunter | Biotech Hunter